BGNE News and Press, BeiGene Ltd. From 04/25/24

2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...

Multiple presentations to showcase the efficacy and safety of BRUKINSA ® across a range of B-cell malignancies Company to present three-year data from RATIONALE-306 study of TEVIMBRA ® in advanced or metastatic esophageal squamous cell carcinoma (ESCC) Be...

2024-04-23 12:15:00 ET More on BeiGene BeiGene Still Bleeding Red Ink Despite Blockbuster Drug BeiGene: Debating On Finally Establishing A Position BeiGene gets FDA approval for esophageal cancer drug Tevimbra BeiGene gains as access to leukemia drug Brukinsa...

Comprehensive development program, including three Phase 3 clinical trials, demonstrated benefit of tislelizumab for patients with treatment-naïve and relapsed NSCLC Decision represents tislelizumab’s second approval in the region BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 0...

A look at the top 10 most actives in the United States Next.e.GO N.V. (EGOX) rose 42.2% to $0.0512 on volume of 330,264,926 shares PROSHARES TRUST (SQQQ) rose 6.4% to $12.84 on volume of 220,628,201 shares AGBA Group Holding Limited (AGBA) rose 21.4% to $1.25 on volume of 128,109,386 shar...

A look at the top 10 most actives in the United States Next.e.GO N.V. (EGOX) rose 94.4% to $0.07 on volume of 92,836,985 shares AGBA Group Holding Limited (AGBA) rose 46.1% to $1.505 on volume of 55,502,222 shares PROSHARES TRUST (SQQQ) rose 1.2% to $12.2099 on volume of 25,933,897 shares...

2024-04-08 11:30:04 ET Bank of America Securities analyst issues NEUTRAL recommendation for BGNE on April 8, 2024 09:28AM ET. The previous analyst recommendation was Neutral. BGNE was trading at $149.29 at issue of the analyst recommendation. The overall analyst consensu...

2024-03-24 07:15:00 ET Summary Shanghai WuXi Biologics (HK: 2269) has broken ground on a $1.4 billion facility in Singapore, the first CRDMO to offer end-to-end biologics research, development and manufacturing in the city-state. Novo Nordisk announced plans to invest $556 million...

2024-03-14 18:46:24 ET More on BeiGene BeiGene Still Bleeding Red Ink Despite Blockbuster Drug BeiGene: Debating On Finally Establishing A Position BeiGene gains as access to leukemia drug Brukinsa expands BeiGene gets FDA accelerated approval for Brukinsa fo...

Results from the global, Phase 3 RATIONALE 302 trial showed TEVIMBRA prolonged the survival of patients who received prior systemic treatment compared to chemotherapy Approval represents the first indication in the U.S. for TEVIMBRA BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE:...